900 Participants Needed

Telemedicine Screening for Glaucoma

(SIGHT Trial)

SW
Overseen BySuzanne Winter, MS
Age: 18+
Sex: Any
Trial Phase: Academic
Sponsor: University of Michigan
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

Trial Summary

Will I have to stop taking my current medications?

The trial information does not specify whether you need to stop taking your current medications.

What data supports the effectiveness of the treatment Standard optometric examination, Technology enhanced eye disease detection protocol for glaucoma?

Research shows that telemedicine programs, like the Technology-Based Eye Care Services (TECS), can effectively detect eye diseases and are comparable to in-person exams, although they are slightly less sensitive for glaucoma. Additionally, using intraocular pressure measurements in telemedicine screenings improves the accuracy of glaucoma diagnoses.12345

Is telemedicine screening for glaucoma safe for humans?

The Teleglaucoma Initiative at a Veterans Affairs Hospital evaluated the safety of telemedicine for glaucoma care and found it to be safe for use in delivering specialized eye care to patients.24567

How is the telemedicine screening for glaucoma treatment different from other treatments?

This treatment is unique because it uses telemedicine (remote healthcare services) to screen for glaucoma, allowing for early detection in remote or rural areas where access to traditional eye care facilities may be limited. It combines portable devices with telemedicine to improve accessibility and accuracy in diagnosing glaucoma.12458

What is the purpose of this trial?

To compare eye disease detection rates at a Federally Qualified Health Center between a technology-enhanced protocol and standard optometric clinical examination for three of the leading causes of blindness: glaucoma, diabetic retinopathy, and visually significant cataract.

Research Team

PA

Paula Anne Newman-Casey, MD

Principal Investigator

University of Michigan

Eligibility Criteria

This trial is for individuals who visit a Federally Qualified Health Center and are at risk of eye diseases like glaucoma, diabetic retinopathy, or cataracts. Specific eligibility criteria were not provided.

Exclusion Criteria

Cognitive impairment
I experience severe eye pain.
Previously declined participation
See 3 more

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Intervention

Participants receive either a standard optometric examination or a technology-enhanced eye disease detection protocol

6 weeks
1 visit (in-person) for initial assessment, followed by additional visits as needed

Follow-up

Participants are monitored for visual function and quality-of-life after intervention

6 weeks

Treatment Details

Interventions

  • Standard optometric examination
  • Technology enhanced eye disease detection protocol
Trial Overview The study compares two methods to detect eye diseases: a standard optometric exam versus a technology-enhanced detection protocol. It aims to see which method is better at finding the leading causes of blindness.
Participant Groups
2Treatment groups
Experimental Treatment
Group I: Intervention, technology enhanced eye disease detection protocolExperimental Treatment2 Interventions
Participants will receive a technology enhanced eye disease detection protocol from ophthalmic technicians that includes measurements of visual function such as visual acuity, refraction, intraocular pressure, pachymetry, external eye and fundus photography, and optical coherence tomography of the macula and retinal nerve fiber layer. The optometrist at the Federally. Qualified Health Center will then use a protocol to grade the testing and identify eye disease. The results of the grading will inform whether the person receives a brief appointment with the optometrist (if no disease is detected) or an in-depth appointment with the optometrist (if there is disease detected).
Group II: Control, standard optometric examinationExperimental Treatment2 Interventions
Participants will receive usual care with an optometrist with a biomicroscopic exam at the Federally Qualified Health Center to identify eye disease.

Find a Clinic Near You

Who Is Running the Clinical Trial?

University of Michigan

Lead Sponsor

Trials
1,891
Recruited
6,458,000+

Centers for Disease Control and Prevention

Collaborator

Trials
902
Recruited
25,020,000+

References

Glaucoma screening: analysis of conventional and telemedicine-friendly devices. [2016]
Philadelphia Telemedicine Glaucoma Detection and Follow-up Study: Methods and Screening Results. [2022]
The Impact of OCT on Diagnostic Accuracy of the Technology-Based Eye Care Services Protocol: Part II of the Technology-Based Eye Care Services Compare Trial. [2020]
Philadelphia Telemedicine Glaucoma Detection and Follow-up Study: Intraocular Pressure Measurements Found in a Population at High Risk for Glaucoma. [2020]
Telemedicine model to prevent blindness from familial glaucoma. [2016]
Telemedicine screening of glaucoma. [2006]
Teleglaucoma Initiative at a Veterans Affairs Hospital: Pilot Safety Data and Early Experience. [2021]
Alabama Screening and Intervention for Glaucoma and Eye Health Through Telemedicine (AL-SIGHT): Study Design and Methodology. [2023]
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security